Survival from cancer of the ovary in england and wales up to 2001

British Journal of Cancer

Volumn 99, Issue , 2008, Pages S70-S72

  Cooper, N ^a   Quinn, M J ^a   Rachet, B ^b   Mitry, E ^c   Coleman, M P ^b  

^a OFFICE FOR NATIONAL STATISTICS   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; HUMAN; MENSTRUAL CYCLE; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; UNITED KINGDOM; UTERUS CANCER;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ENGLAND; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; SOCIAL CLASS; SURVIVAL ANALYSIS; WALES;

EID: 52449105051     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604593     Document Type: Article

References (12)

1. Brenner H, Rachet B (2004) Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur J Cancer 40: 2494–2501
2. Brewster DH, Thomson CS, Hole DJ, Black RJ, Stroner PL, Gillis CR (2001) Relation between socioeconomic status and tumour stage in patients with breast, colorectal, ovarian, and lung cancer: results from four national, population based studies. Br Med J 322: 830–831
3. Coleman MP, Babb P, Damiecki P, Grosclaude PC, Honjo S, Jones J, Knerer G, Pitard A, Quinn MJ, Sloggett A, De Stavola BL (1999) Cancer Survival Trends in england and wales 1971–1995: Deprivation and NHS Region. Studies on Medical and Population Subjects No. 61. The Stationery Office: London
4. Coleman MP, Estève J, Damiecki P, Arslan A, Renard H (1993) Trends in Cancer Incidence and Mortality (IARC Scientific Publications No. 121). International Agency for Research on Cancer: Lyon
5. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Prys Davies A, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH (1999) Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353: 1207–1210
6. Lewis S, Menon U (2003) Screening for ovarian cancer. Exp Rev AntiCancer Ther 3: 55–62
7. Lister-Sharp D, McDonaugh MS, Khan KS, Kleijnen J (2000) A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol Assess 4: 1–113
8. NHS Centre for reviews and dissemination (1999) Management of gynaecological cancers. Eff Health Care 5: 1–12
9. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds) (2002) Cancer Incidence in Five Continents, Volume VIII (IARC Scientific Publications No. 155). International Agency for Research on Cancer: Lyon
10. Quinn MJ, Babb P, Brock A, Kirby L, Jones J (2001) Cancer Trends in england and wales 1950–1999. Studies on Medical and Population Subjects No. 66. Office for National Statistics: London
11. Rachet B, Woods LM, Mitry E, Riga M, Cooper N, Quinn MJ, Steward J, Brenner H, Estève J, Sullivan R, Coleman MP (2008) Cancer survival in england and wales at the end of the 20th century. Br J Cancer 99(Suppl 1): S2–S10
12. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli P-M, Faivre J, Grosclaude PC, Hédelin G, Matsuda T, Møller H, Moller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D, EUROCARE Working Group (2003) EUROCARE-3: survival of cancer patients diagnosed 1990–94–results and commentary. Ann Oncol 14(Suppl 5): 61–118